Should I buy Mylan stock in 2025?

What is Mylan?

How much is the Mylan stock?

The price of Mylan stock is rising this week. As of now, the stock is trading at $8.83, showing a 2.79% gain in the past 24 hours and a positive 4.13% over the last seven days.

With a stock beta of 0.89, Mylan typically exhibits lower volatility than the US market—important for SA investors considering stable pharmaceutical sector exposure.

Our full analysis on the Mylan stock

Having rigorously reviewed Mylan’s (now Viatris Inc.) latest quarterly financial results, as well as the stock’s multi-year trajectory and peer benchmarks, we’ve employed a combination of market data, technical signals, and proprietary financial models to present a clear analysis. Our systems integrate a broad spectrum of valuation metrics and qualitative sector insights to assess where compelling opportunities may be emerging. So, why might Mylan stock again represent a strategic entry point into the global pharmaceutical sector in 2025?

Recent Performance and Market Context

Over the past twelve months, Mylan (trading as Viatris, NASDAQ: VTRS) has exhibited a notable consolidation after a volatile period, currently priced at $8.83 as of 30 May 2025. This reflects a positive intraday move of +2.79% and a tangible rise of +4.13% over the past week and +5.88% over the preceding month. While the six-month and annual trajectories remain mildly negative (-32.54% and -14.35% respectively), the latest price action signals a potential shift in investor sentiment, aligning with recovering sector appetite.

Several positive catalysts have surfaced recently. The company has announced Phase 3 clinical trial successes for lead pipeline products—cenerimod for systemic lupus and sotagliflozin addressing cardiovascular disease. Anticipation is also building for up to six Phase 3 data readouts in 2025, suggesting potentially transformative news flow ahead. These advancements land against an improving macro backdrop for healthcare and pharmaceuticals, with defensive and high-dividend equities increasingly favoured in diversified ZA and global portfolios as economic cycles mature.

Despite regulatory headwinds—most notably a U.S. FDA import alert impacting the Indore facility in India—the impact appears contained and largely factored into consensus expectations, with risk mitigation strategies swiftly enacted by management. Notably, the company retains its status as a leading generic drug provider worldwide, now serving patients in over 165 countries.

Technical Analysis

From a technical perspective, Viatris’ chart structure, alongside major indicators, reflects clear undertones of emerging strength:

• RSI (14 days) stands at 69.01—a value approaching overbought but typically characteristic of sustained bullish momentum during inflection points.
• MACD (12,26) is positive, at 0.05, affirming an active buy signal and supporting the thesis of a nascent trend reversal.
• Short- and medium-term moving averages are aligned bullishly:
• The 5-day ($8.75), 20-day ($8.63), 50-day ($8.58), and 200-day ($8.49) moving averages all trail current pricing, indicating robust trend support and the emergence of a “golden cross” structure.
• Key support is identified at $8.57, with a major near-term resistance at $8.85—a breakout above which could catalyse further momentum, should positive catalysts materialise.

The technical consensus as of end-May rates VTRS as a “strong buy,” with short- and mid-term patterns suggesting that value-oriented buyers have been accumulating into recent weakness, seeking exposure at historic technical lows.

Fundamental Analysis

On the fundamental front, Mylan/Viatris offers an attractive combination of scale, resilience, and forward-looking growth potential:

• 2024 revenues reached $14.7 billion, with a solid free cash flow of $2.0 billion and adjusted EBITDA of $4.7 billion. Despite a modest 2% core operating growth (excluding divestitures), these figures underscore robust cash generation.
• Dividend yield stands out at an appealing 5.44% ($0.48/share annualised), providing steady income even during periods of price volatility—a compelling characteristic for yield-seeking ZA investors amid global rate uncertainty.
• Valuation multiples remain modest, as market cap sits at $10.35 billion, and a beta of 0.89 signals below-market volatility. While GAAP earnings remain negative (P/E N/A), the underlying operating fabric is sound, with profitability expected to rebound post-regulatory headwinds.
• The company is executing a strategic share buyback programme ($500-650 million planned for 2025), enhancing per-share value and reinforcing management’s conviction in the long-term outlook.
• Viatris’ pipeline is credible: with patent-protected assets, biosimilars, and specialty drugs all contributing to a diversified portfolio and significant addressable market. With access to nearly one billion patients annually, the group is exceptionally well positioned to capitalise on both mature and emerging markets.

Structurally, the brand remains a global leader in generics—a sector known for defensive, recession-resistant demand—and is pushing further into higher-margin, innovative medication classes, enhancing the risk/reward profile.

Volume and Liquidity

Trading liquidity is consistently robust, with a 3-month average daily volume of approximately 15.15 million shares. This elevated activity validates continued institutional participation and reflects resilient market confidence in the stock’s underlying value proposition.

The free float is substantial, with 1.17 billion shares outstanding, supporting efficient price discovery and maintaining a dynamic environment for both long-term investors and tactical traders seeking exposure ahead of catalysts.

Catalysts and Positive Outlook

The next twelve months present several catalysts that set the stage for potential re-rating:

• Pipeline milestones: Up to six Phase 3 clinical data readouts are on deck for 2025, notably for cenerimod, selatogrel, and sotagliflozin. Positive trial outcomes could materially reframe Viatris' revenue potential and valuation.
• Product launches: Management aims for $450–550 million in new-product revenues over the coming year.
• Share buybacks: The $500–650 million repurchase programme reinforces shareholder returns and acts as a potential price floor, signalling management’s confidence.
• ESG and global footprint: The company’s reach in over 165 markets, and its accessibility for over a billion patients, amplifies the social value aspect, catering to ESG-focused capital seeking exposure to improvements in global health.
• Resilient macro trends: Demand for affordable medicines remains robust globally, while reforms and rising healthcare spend in key emerging markets (including Africa and the broader EMEA region) stand to benefit leaders in generic and biosimilar medicines.

The consensus analyst price target stands at $11.60 (+31.42%), with market models projecting 30% medium-term upside—a notably attractive proposition as the broader sector rotates towards quality, cash-generative and high-dividend stocks.

Investment Strategies

Mylan/Viatris appears well suited for a multitude of investment horizons:

• Short-term:
• Recent positive technical signals, combined with robust volume and a cluster of support levels around $8.57, create an appealing set-up for tactical buying. Anticipated pipeline updates or positive news flow have the potential to drive near-term price appreciation.
• Medium-term:
• The next wave of clinical trial readouts and incremental improvements in regulatory sentiment could result in successive rerating episodes, particularly as the buyback programme absorbs market liquidity.
• Long-term:
• For investors seeking exposure to healthcare’s secular growth, Viatris constitutes a cornerstone holding. Its defensive business model, reliable dividend, and innovation-driven strategy combine to underpin compounding returns potential, independent of broader market volatility.

Optimal entry points may be present near technical lows, with positioning ahead of key data releases maximising the risk/reward payoff. The liquidity profile supports scaling positions as conviction builds.

Is It the Right Time to Buy Mylan?

Examining the confluence of factors—constructive technical trends, deep undervaluation versus global peers, strong dividend and buyback commitments, and a deep innovation pipeline—Mylan/Viatris stands out as a stock that may be approaching a new bullish phase. The current price consolidation, underpinned by robust market structures and visible near-term catalysts, seems to represent an excellent opportunity for investors seeking quality exposure to the pharmaceutical sector with strong defensive characteristics.

While short-term risks such as regulatory scrutiny and ongoing competitive pressure remain, these are increasingly being offset by Viatris’ global operational scale, strong brand, and proven ability to innovate within generics and specialty medicine segments.

Given the stock’s moderate volatility profile and compelling upside illustrated by a consensus price target over 30% above current levels, calibrated investors may find renewed interest in positioning ahead of catalyst-rich periods. As dynamic global trends continue to elevate the healthcare sector on both local and international stages, Mylan appears ready not only to participate, but to potentially lead in value creation for well-positioned portfolios.

Ultimately, for ZA and international investors alike, the confluence of solid fundamentals, healthy yield, and a transformative outlook underscore why Mylan could soon re-emerge as a strategic portfolio entry for 2025 and beyond—making this a name to watch with decisive optimism in the months ahead.

How to buy Mylan stock in ZA?

Buying Mylan (now Viatris) stock online is straightforward and secure when you use a regulated broker in South Africa. Investors have two main options: purchasing shares outright (spot or cash buying) to own the stock, or trading via CFDs (Contracts for Difference) to profit from price changes without owning the asset. Each method has its benefits in terms of ownership, fees, and flexibility. Your personal objectives and experience will determine the right approach. For your convenience, a comprehensive broker comparison is available further down the page to help you make the best choice.

Spot (Cash) Buying

A cash purchase means you buy Mylan (Viatris) shares directly and become a shareholder, with all associated rights, such as receiving dividends. Most South African brokers charge a fixed commission per order, typically between R70 and R150, or a low percentage (often around 0.1% – 0.5%) of the transaction value.

Example

Suppose the current share price is $8.83 (roughly R165 at an exchange rate of R18.7/USD). With a $1,000 stake (around R18,700), excluding currency conversion costs, you could buy approximately 113 shares of Viatris (Mylan), after accounting for a typical $5 (R94) broker fee.

Gain scenario

If the share price rises by 10%, your shares are now worth $1,100 (R20,570).

Result: +$100 gross gain (R1,870), a 10% return on your original investment.

Trading via CFDs

CFDs (Contracts for Difference) allow you to speculate on Mylan’s (Viatris’) share price without owning the underlying stock, using leverage to amplify your exposure. Trading CFDs involves costs like the bid/ask spread and overnight financing fees for positions held longer than a day.

Example

You invest $1,000 in a CFD position on Mylan shares with 5x leverage, giving you exposure to $5,000 worth of shares.

Gain scenario

If the stock price rises by 8%, your CFD position increases by 8% × 5 = 40%.

Result: +$400 gain on a $1,000 margin (before fees and costs).

Final Advice

Before investing in Mylan (Viatris) shares, it’s essential to compare brokers’ fees, platform features, currency conversion charges, and customer support—these can all affect your final return. Whether you choose spot buying for long-term ownership and potential dividends, or CFD trading for flexibility and leverage, your preferred method should match your investment objectives and risk tolerance. Ready to take the next step? Find the broker comparison tool further down the page to select the platform that fits your needs.

Our 7 tips for buying Mylan stock

The latest news about Mylan

Mylan (Viatris) stock experienced a strong recovery, gaining over 4% in the last week. This rebound is supported by positive technical signals, with the stock trading at $8.83 and closing out the month with a +2.79% intraday increase. All principal short- and medium-term moving averages (5, 20, 50, and 200 days) signal a buy, and the RSI at 69 confirms persistent upward momentum, bordering on overbought territory. For South African investors, the resilience and renewed momentum of Viatris could translate into notable ADR interest on local platforms, especially given its NASDAQ primary listing and relevance to emerging market portfolios.

Viatris’ dividend yield remains highly attractive at 5.44%, surpassing most peers and local pharma alternatives. Dividend-paying stocks are often favored in South Africa for income-generation strategies, and Viatris’ quarterly dividend adds a defensive dimension to portfolios exposed to global pharmaceuticals. The company’s commitment to this payout, even in a year of operational headwinds, offers stability for investors in regions like South Africa, where currency volatility and inflation heighten the appeal of high-yielding US equities.

Recent results from late-stage clinical trials have delivered positive data for cenerimod and sotagliflozin, underpinning future growth prospects. These developments are especially relevant to South Africa, which continues to battle high rates of lupus and cardiovascular diseases—areas targeted by these two drugs. Medium-term, these medicines could enhance Viatris’ product mix in emerging markets, expanding healthcare access and supporting local distributors and partners involved in the launch and supply of new, affordable therapies.

The company's 2025 guidance for new product revenues ($450-550 million) and a $500-650 million buyback program are expected to support further stock appreciation. South African asset managers focusing on US-listed pharma companies will note the significant return of capital to shareholders as a sign of robust balance sheet management. The healthy pipeline—with six Phase 3 results due in 2025—is a positive catalyst for international investors monitoring healthcare innovation and upcoming launches in Southern Africa, where Viatris is historically present through the former Mylan brand.

Despite the temporary FDA import alert on Viatris' Indore facility, the firm’s global footprint and diversified portfolio remain strong and relevant for the African market. While the regulatory setback has a projected $500 million revenue impact, it has not compromised the firm’s global servicing capability. Viatris’ ability to supply a broad range of generics and biosimilars to the South African healthcare system, amid international regulatory headwinds, affirms its reliability as a major partner for private and public sector entities locally. Continued commitment to market presence ensures medical supply stability, a factor that positively influences institutional sentiment in the local context.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.